In 2000, neurosurgeon Kevin Tracey discovered that electrical stimulation of the vagus nerve in mice dramatically reduced systemic inflammation, even after the animals had been injected with lethal doses of bacterial endotoxin. The mechanism — now called the cholinergic anti-inflammatory pathway — revealed that the nervous system actively regulates immune function in real time. This discovery created an entirely new field, bioelectronic medicine, and opened a direct line of investigation into whether vagus nerve stimulation could treat autoimmune diseases where inflammation drives tissue destruction.
The Cholinergic Anti-Inflammatory Pathway
The pathway works through a specific circuit. Vagal afferent fibres detect peripheral inflammation via cytokine receptors and relay that information to the brainstem’s nucleus tractus solitarius. The brain processes the signal and activates vagal efferent output, which travels to the coeliac ganglion in the abdomen. From there, splenic nerve fibres release noradrenaline in the spleen, which activates a subset of T cells (CD4+ ChAT+ T cells) that produce acetylcholine. This acetylcholine binds alpha-7 nicotinic acetylcholine receptors (a7nAChR) on macrophages, suppressing their production of TNF-alpha, IL-1beta, IL-6, and HMGB1 — the principal pro-inflammatory cytokines that drive tissue damage in autoimmune disease.
The specificity of this pathway matters. It does not broadly suppress immunity in the way that corticosteroids or methotrexate do. The a7nAChR signal specifically reduces pro-inflammatory cytokine production while leaving anti-microbial functions — phagocytosis, antigen presentation, and adaptive immune responses — largely intact. This selective mechanism is what makes vagal modulation potentially superior to conventional immunosuppression for autoimmune conditions: it targets the inflammatory component without crippling the immune system’s ability to fight infection.
Rheumatoid Arthritis: The Landmark Clinical Evidence
Rheumatoid arthritis (RA) became the first autoimmune disease to be treated with an implanted vagus nerve stimulator in a formal clinical trial. The SetPoint Medical study, published in Proceedings of the National Academy of Sciences in 2016, implanted miniature VNS devices in 17 RA patients who had failed conventional therapies. Within 12 weeks, the majority showed significant reductions in disease activity scores (DAS28-CRP). TNF-alpha levels in blood dropped measurably, and several patients achieved clinical remission — outcomes they had not achieved on biologics.
A key finding was that the anti-inflammatory effect persisted even when stimulation was paused for a period and then restarted, suggesting that the device was retraining the immune system rather than simply suppressing it during active stimulation. Follow-up data presented at the American College of Rheumatology meetings in subsequent years showed sustained benefit over 24 months with daily 60-second stimulation sessions.
RA patients also show measurably reduced vagal tone compared with healthy controls. Multiple studies using heart rate variability as a vagal tone proxy have found that lower HRV correlates with higher disease activity, higher CRP levels, and higher joint counts. This suggests that impaired vagal regulation may be not just a consequence of chronic illness but a contributing factor that permits inflammation to escalate.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,684 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- Polyvagal-informed therapy
- Somatic therapy
- HRV biofeedback
- Craniosacral therapy
- Breathwork
- Insomnia therapy (CBT-I)
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
Inflammatory Bowel Disease
Crohn’s disease and ulcerative colitis involve chronic inflammation of the gastrointestinal tract — territory directly innervated by the vagus nerve. The vagus nerve’s anti-inflammatory effect in the gut operates through both the systemic splenic pathway and local enteric circuits where vagal fibres interact with macrophages in the intestinal muscularis layer.
A pilot study from INSERM (France) published in Neurogastroenterology and Motility in 2016 implanted VNS devices in seven patients with moderate-to-severe Crohn’s disease. Five of seven achieved clinical remission at 6 months, with endoscopic improvement confirmed in several patients. CRP levels decreased, and faecal calprotectin — a direct marker of intestinal inflammation — dropped substantially.
Transcutaneous auricular VNS (taVNS) is being investigated as a non-invasive alternative for IBD. A 2023 randomised controlled trial in Bioelectronic Medicine found that 12 weeks of daily taVNS in Crohn’s patients reduced faecal calprotectin and improved quality-of-life scores compared with sham stimulation. The effect sizes were smaller than those seen with implanted VNS, consistent with the lower vagal fibre recruitment achieved by surface stimulation, but the results were statistically significant.
Other Autoimmune Conditions Under Investigation
Systemic lupus erythematosus (SLE). Animal models of lupus treated with VNS show reduced anti-dsDNA antibodies, lower proteinuria (a marker of lupus nephritis), and improved survival. Human studies are in early phases. SLE patients have consistently demonstrated reduced vagal tone on HRV analysis, and the degree of autonomic dysfunction correlates with disease activity and organ damage scores.
Multiple sclerosis (MS). VNS in experimental autoimmune encephalomyelitis (the mouse model of MS) reduces demyelination and immune cell infiltration into the central nervous system. The proposed mechanism involves suppression of Th17 cell differentiation — a T-cell subtype that drives autoimmune CNS inflammation. Human clinical trials of VNS for MS are in the planning stage but have not yet reported results.
Psoriasis. A 2020 proof-of-concept study treated psoriasis patients with transcutaneous cervical VNS (gammaCore device) for 12 weeks. Treated patients showed improvement in Psoriasis Area and Severity Index (PASI) scores. The rationale is that psoriatic inflammation is driven partly by TNF-alpha and IL-17, both of which are downstream targets of the cholinergic anti-inflammatory pathway.
Type 1 diabetes. Vagal stimulation in NOD mice (the standard model for type 1 diabetes) delayed the onset of diabetes and reduced islet cell destruction. The mechanism appears to involve modulation of the immune attack on pancreatic beta cells. Human data are not yet available.
Vagal Tone as a Biomarker for Autoimmune Risk
Beyond treatment, vagal tone measured by HRV may serve as a biomarker for autoimmune disease activity and flare risk. A 2021 study in Autoimmunity Reviews proposed that HRV monitoring could predict disease flares in RA and IBD days before clinical symptoms appear, based on the observation that vagal tone drops measurably in the 48 to 72 hours preceding a flare. If validated in larger studies, this could enable pre-emptive treatment adjustments guided by autonomic monitoring.
The inverse relationship between vagal tone and systemic inflammation (measured by CRP, IL-6, and TNF-alpha) has been confirmed in large population studies independent of specific autoimmune diagnoses. The Framingham Heart Study offspring cohort found that individuals in the lowest quartile of vagal tone had significantly higher inflammatory markers, suggesting that vagal function may be a general modifier of inflammatory disease risk.
Practical Approaches
While implanted VNS devices remain investigational for autoimmune conditions (approved only for epilepsy and treatment-resistant depression as of 2025), non-invasive vagal tone improvement may complement standard autoimmune therapies. Slow breathing at six breaths per minute for 15 minutes daily has been shown to increase HRV and reduce CRP in patients with chronic inflammatory conditions. Regular moderate aerobic exercise (150 minutes per week) improves vagal tone and reduces inflammatory markers across multiple autoimmune diagnoses. Omega-3 fatty acid supplementation at doses above 2 grams daily has demonstrated both vagal tone improvement and anti-inflammatory effects in RA trials.
These interventions do not replace disease-modifying therapies. Autoimmune diseases require management by a rheumatologist, gastroenterologist, or other specialist, and decisions about medications should be made within that clinical relationship. Vagal tone optimisation is best understood as an adjunct — a way to strengthen the body’s endogenous anti-inflammatory capacity while standard treatments address the immune dysregulation directly.
For a comprehensive guide to how the vagus nerve regulates immunity and inflammation — and what you can do to support that process — get the Vagus Nerve & Me eBook and understand the science behind bioelectronic medicine.




